Trial Profile
24-month Randomized, Double-masked, Controlled, Multicenter, Phase II Study Assessing Safety and Efficacy of Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab Versus Ranibizumab Monotherapy in Patients With Subfoveal Choroidal Neovascularization Secondary to AMD.
Status:
Suspended
Phase of Trial:
Phase II/III
Latest Information Update: 28 Sep 2015
Price :
$35
*
At a glance
- Drugs Verteporfin (Primary) ; Ranibizumab
- Indications Age-related macular degeneration; Choroidal neovascularisation
- Focus Therapeutic Use
- Sponsors Novartis
- 28 Sep 2015 New trial record